Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2295-2305

  Moffat Jr , F L ^a   Pinsky, C M ^a   Hammershaimb, L ^a   Petrelli, N J ^a   Patt, Y Z ^a   Whaley, F S ^a   Goldenberg, D M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARCITUMOMAB TC 99M; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY IMMU 4; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; GASTROINTESTINAL TRACT SCINTISCANNING; HUMAN; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; RECTUM CARCINOMA;

EID: 9444289885     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2295     Document Type: Article

References (54)

1. Moertel CG, Fleming TR, MacDonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 322:352-358, 1990
2. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high risk rectal carcinoma. New Engl J Med 324:709-715, 1991
3. August DA, Ottow RT, Sugarbaker PH: Clinical perspectives on human colorectal cancer metastases. Cancer Metastasis Rev 3:303-324, 1984
4. Steele G Jr: Follow-up plans after treatment of primary colon and rectal cancer. World J Surg 15:583-588, 1991
5. Quentmeier A, Schlag P, Smok M: Re-operation for recurrent colorectal cancer: The importance of early diagnosis for resectability and survival. Eur J Surg Oncol 16:319-325, 1990
6. Galandiuk S, Wieand HS, Moertel CG, et al: Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 174:27-32, 1992
7. Goldenberg DM, DeLand F, Kim E, et al: Use of radiolabeled antibodies to carcinoembryonic antigen in the detection and localization of diverse cancers by external photoscanning. New Engl J Med 298:1384-1388, 1978
8. Beatty JD, Hyams DM, Morton BA, et al: Impact of radiolabeled antibody imaging on management of colorectal cancer. Am J Surg 157:13-19, 1989
9. Winzelberg GG, Grossman SJ, Rizk S, et al: Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Cancer 69:1656-1663, 1992
10. Serafini AN, Vargas-Cuba RD, Benedetto P, et al: Clinical experience in utilizing radiolabeled monoclonal antibodies. Antibody Immunoconj Radiopharm 4:77-83, 1991
11. 99mTc-IMMU-4 monoclonal antibody scan in colorectal cancer. A prospective study. Arch Surg 127:1321-1324, 1992
12. Moffat FL, Vargas-Cuba RD, Serafini AN, et al: Radioimmunodetection of colorectal carcinoma using technetium-99m-labeled Fab' fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer 73:836-845, 1994
13. Corbisiero RM, Yamauchi DM, Williams LE, et al: Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: Individual lesion analysis. Cancer Res 51:5704-5711, 1991
14. Doerr RJ, Abdel-Nabi H, Krag DN, et al: Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg 214:118-124, 1991
15. Collier BD, Abdel-Nabi H, Doerr RJ, et al: Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: Comparison with CT. Radiology 185:179-186, 1992
16. Primus FJ, Newell KD, Blue A, et al: Immunological heterogeneity of carcinoembryonic antigen. 2. Antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 43:686-692, 1983
17. Serafini AN, Goldenberg DM, Higginbotham-Ford EA, et al: A multicenter trial of cancer imaging with fragments of CEA monoclonal antibodies. J Nucl Med 30:748, 1989 (abstr)
18. 99mTc. Cancer Res 50:909s-921s, 1990 (suppl)
19. Goldenberg DM, Wlodkowski TJ, Sharkey RM, et al: Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 34:61-70, 1993
20. Losman MJ, DeJager RL, Monestier M, et al: Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies. Cancer Res 50:1055s-1058s, 1990 (suppl)
21. Goldenberg DM, Larson SM: Radioimmunodetection in cancer identification. J Nucl Med 33:803-814, 1992
22. Swayne LC, Goldenberg DM, Diehl WL, et al: SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases. Clin Nucl Med 16:849-852, 1991
23. Podoloff DA, Patt YZ, Curley SA, et al: Imaging of colorectal carcinoma with technetium-99m radiolabeled Fab' fragments. Semin Nucl Med 23:89-98, 1993
24. Patt YZ, Podoloff DA, Curley S, et al: Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol 12:489-495, 1994
25. 99mTc-labeling kit for antibody imaging. Cancer Res 50:794s-798s, 1990 (suppl)
26. Serafini AN, Vargas-Cuba RD, Benedetto P, et al: Tc-99m-Fab' fragment of anti-CEA monoclonal antibody for the radioimmunodetection of colorectal adenocarcinoma. Antibody Immunoconj Radiopharm 4:561-568, 1991
27. Conover WJ: Practical Nonparametric Statistics (ed 2). New York, NY, Wiley, 1980, pp 99-104
28. Armitage P: Test for linear trend in proportions and frequencies. Biometrics 11:376-386, 1955
29. Blend MJ, Ronan SG, Salk DJ, et al: Role of technetium 99m-labeled monoclonal antibody in the management of melanoma patients. J Clin Oncol 10:1330-1337, 1992
30. 99mTc-labeled Fab' fragment reactive with a high molecular weight melanoma antigen. Cancer Res 50:904s-908s, 1990 (suppl)
31. Abdel-Nabi H, Wright GL, Gulfo JV, et al: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 10:45-54, 1992
32. Granowska M, Mather SJ, Jobling T, et al: Radiolabeled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumors. Int J Biol Markers 5:89-96, 1990
33. 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol 48:285-292, 1993
34. 2 in the preoperative detection of clinical and subclinical lymph node metastases in breast cancer patients. Int J Cancer 3:89-95, 1988 (suppl)
35. Tjandra JJ, Sacks NPM, Thompson CH, et al: The detection of axillary lymph node metastases from breast cancer by radiolabeled monoclonal antibodies: A prospective study. Br J Cancer 59:296-302, 1989
36. Abdel-Nabi H, Schwartz AN, Wechter DG, et al: Scintigraphic detection of gastric and pancreatic carcinomas with In-111 ZCE025 monoclonal antibody. World J Surg 15:122-127, 1991
37. Goldenberg DM, Goldenberg H, Sharkey RM, et al: Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 19:262-281, 1989
38. Haseman MK, Brown DW, Keeling CA, et al: Radioimmunodetection of occult carcinoembryonic antigen-producing cancer. J Nucl Med 33:1750-1757, 1992
39. 2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 77:301-311, 1986
40. Patt YZ, Podoloff DA, Curley S, et al: Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen. Cancer 71:4293-4297, 1993
41. Abdel-Nabi H, Doerr RJ, Chan H-W, et al: In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: Safety, sensitivity and preliminary clinical results. Radiology 175:163-171, 1990
42. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:814s-819s, 1990 (suppl)
43. Abdel-Nabi H, Doerr RJ: Radiolabeled monoclonal antibody imaging (immunoscintigraphy) of colorectal cancers: Current status and future perspectives. Am J Surg 163:448-456, 1992
44. 111In-CYT-103; Oncoscint CR103) in patients with colorectal carcinoma, in Maguire RT, Van Nostrand D (eds): Diagnosis of Colorectal and Ovarian Carcinoma. Application of Immunoscintigraphic Technology. New York, NY, Dekker, 1992, pp 73-88
45. 99mTc: The role of metabolism and kinetics. Cancer Res 55:5777s-5785s, 1995 (suppl)
46. Reynolds JC, Del Vecchio S, Sakahara H, et al: Anti-murine antibody response to mouse monoclonal antibodies: Clinical findings and implications. Nucl Med Biol, Int J Radiat Appl Instrum Part B 16:121-125, 1989
47. Carrasquillo JA, Sugarbaker P, Colcher D, et al: Radioimmunoscintigraphy of colon cancer with iodine-131 labeled B72.3 monoclonal antibody. J Nucl Med 29:1022-1030, 1988
48. Blottiere HM, Douillard JY, Koprowski H, et al: Immunoglobulin class and immunoglobulin G subclass analysis of human anti-mouse antibody response during monoclonal antibody treatment of cancer patients. Cancer Res 50:1051s-1054s, 1990 (suppl)
49. Primus JA, Kelly EA, Hansen HJ, et al: "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 34:261-264, 1988
50. Morton BA, O'Connor-Tressel M, Beatty BG, et al: Artifactual CEA elevation due to human anti-mouse antibodies. Arch Surg 123:1242-1246, 1988
51. Hansen HJ, LaFontaine G, Newman ES, et al: Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen. Clin Chem 35:146-151, 1989
52. Schroff RW, Foon KA, Beatty SM, et al: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879-885, 1985
53. Courtenay-Luck NS, Epenetos AA, Moore R, et al: Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489-6493, 1986
54. Hughes K, Pinsky C, Petrelli N, et al: Use of radioimmunodetection with CEA-Scan in planning for resection of recurrent colorectal cancer. J Am Soc Clin Oncol 14:544, 1995 (abstr)